Idalid Franco

Idalid Franco

Auto-generated profile, based on publicly available information

Idalid Franco

Brigham and Women’s Hospital and Dana-Farber Cancer Institute

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in JCO Oncology Practice
Verified
Journal Article
Open access
NDNarjust Duma
Narjust Duma
AVAna I. Velazquez
Ana I. Velazquez
IFIdalid Franco
Idalid Franco
LKLauren Kiel
Lauren Kiel
LLLaura A. Levit
Laura A. Levit
GRGladys Rodriguez
Gladys Rodriguez
This manuscript reviews the status of Hispanic/Latinx physicians in oncology, the benefits and challenges to achieving equitable representation, and potential solutions and actions to increase diversity in the oncology workforce. Persons of Hispanic/Latinx origin comprise 18.7% of the population and 16.8% of the adult population in the United States but are only 4.7% of practicing oncologists. The reasons for the lack of representation of Hispanic/Latinx individuals in medicine are multifaceted and include discrimination and biases, exclusionary practices, financial barriers, and lack of role modeling. As a result, patients are deprived the benefits of a representative workforce, such as improved access, enhanced culturally and linguistically competent care, and minimization of health disparities. Solutions included in the manuscript include a description of efforts by ASCO to improve the representativeness of the oncology workforce through its awards programs and educational efforts, especially for Hispanic/Latinx clinicians. The manuscript also outlines individual actions that attending physicians, senior oncologists, oncology leaders, and hospital/cancer center leadership can take to improve the diversity of the oncology workforce and support our Latinx/Hispanic trainees and colleagues. Improving the representativeness of the oncology workforce will require collective action by institutions, medical societies, and individuals. Nevertheless, widespread commitment to creating an inclusive and supported workforce is necessary to ensure the quality of care for minority patients, reduce existing cancer care disparities, and advance innovation in oncology.

11 August 2022 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
NSNishwant Swami
Nishwant Swami
TNTiffany Nguyen
Tiffany Nguyen
EDEdward Christopher Dee
Edward Christopher Dee
IFIdalid Franco
Idalid Franco
YBYefri A. Baez
Yefri A. Baez
FCFumiko Chino
Fumiko Chino

12 January 2022 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
MAMohammed Alshalalfa
Mohammed Alshalalfa
CSCrystal Seldon
Crystal Seldon
IFIdalid Franco
Idalid Franco
RVRandy Vince
Randy Vince
RCRuben Carmona
Ruben Carmona
BMBrandon A. Mahal
Brandon A. Mahal

7 March 2022 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
IFIdalid Franco
Idalid Franco
AVAkila N Viswanathan
Akila N Viswanathan
Worldwide, stage III–IVA carcinomas of the uterine cervix comprise a significant proportion of cases at presentation, and have a higher rate of recurrence and worse overall survival. This review will discuss the epidemiology, prevention strategies, clinical presentation, and treatment recommendations for stage III–IVA cervical cancer. The focus will be on the role of radiation therapy, concurrent chemoradiotherapy, and brachytherapy, including the potential benefits and anticipated toxicities. The unique challenges and considerations of fistula formation and approaches to management will be highlighted, and follow-up care and future directions discussed. As low and middle income countries bear the highest burden of advanced stage carcinoma of the uterine cervix, this review will address the unique needs of global communities.

1 January 2021 in Advances in Radiation Oncology
Verified
Journal Article
Open access
IFIdalid Franco
Idalid Franco
OOOluwadamilola T. Oladeru
Oluwadamilola T. Oladeru
ASAnurag Saraf
Anurag Saraf
KLKevin X. Liu
Kevin X. Liu
MMMichael Milligan
Michael Milligan
RJRachel Jimenez
Rachel Jimenez
In response to the coronavirus disease 2019 pandemic, current Association of American Medical Colleges guidelines discourage away rotations, posing significant challenges for attracting students to radiation oncology (RO). This is particularly concerning for medical students underrepresented in medicine (UIM) due to the potential of widening existing disparities in applicant and workforce composition. To proactively address this, we created a Radiation Oncology Intensive Shadowing Experience (RISE) to expose UIM students to the field of RO. Key stakeholders within the residency program, including both UIM faculty and residents with experience in health disparities and medical education, designed a 1-week virtual RISE intended for fourth year UIM students recruited through established national organizations serving UIM medical students. A 1-week disease-specific curriculum was developed using 4 components: (1) foundational exposure to RO, (2) didactic teaching, (3) mentorship opportunities, and (4) a capstone experience. Mentorship was continuously weaved through the experience by attendings, peer resident mentors, and a UIM resident panel to optimize exposure. RISE was successfully initiated at 2 academic medical centers with 12 UIM students enrolled through August. Anonymized pre- and postclerkship surveys were developed for students, residents, and faculty involved in RISE to evaluate participants’ satisfaction, resident and attending time burden, and perceptions of program effectiveness. We created a unique virtual RO shadowing experience for UIM students to address a critical gap in exposure to RO, heightened by the corona virus disease 2019 pandemic, with the goal of improving diversity, equity, and inclusion in our field.

1 April 2024 in JCO Oncology Practice
Verified
Journal Article
Closed access
EDEdward Christopher Dee
Edward Christopher Dee
NSNishwant Swami
Nishwant Swami
BKBahaa Kazzi
Bahaa Kazzi
KLKaitlyn Lapen
Kaitlyn Lapen
IFIdalid Franco
Idalid Franco
DGDaniel R. Gomez
Daniel R. Gomez
PURPOSE: Hispanic and Latinx people in the United States are the fastest-growing ethnic group. However, previous studies in non–small-cell lung cancer (NSCLC) often analyze these diverse communities in aggregate. We aimed to identify differences in NSCLC stage at diagnosis in the US population, focusing on disaggregated Hispanic/Latinx individuals. METHODS: Data from the National Cancer Database from 2004 to 2018 identified patients with primary NSCLC. Individuals were disaggregated by racial and ethnic subgroup and Hispanic country of origin. Ordinal logistic regression adjusting for age, facility type, income, educational attainment, comorbidity index, insurance, and year of diagnosis was used to create adjusted odds ratios (aORs), with higher odds representing diagnosis at later-stage NSCLC. RESULTS: Of 1,565,159 patients with NSCLC, 46,616 were Hispanic/Latinx (3.0%). When analyzed in the setting of race and ethnicity, Hispanic patients were more likely to be diagnosed with metastatic disease compared with non-Hispanic White (NHW) patients: 47.0% for Hispanic Black, 46.0% Hispanic White, and 44.3% of Hispanic other patients versus 39.1% of non-Hispanic White patients ( P < .001 for all). By country of origin, 51.4% of Mexican, 41.7% of Puerto Rican, 44.6% of Cuban, 50.8% of South or Central American, 48.4% of Dominican, and 45.6% of other Hispanic patients were diagnosed with metastatic disease, compared with 39.1% of NHWs. Conversely, 20.2% of Mexican, 26.9% of Puerto Rican, 24.2% of Cuban, 22.5% of South or Central American, 23.7% of Dominican, and 24.5% of other Hispanic patients were diagnosed with stage I disease, compared with 30.0% of NHWs. All Hispanic groups were more likely to present with later-stage NSCLC than NHW patients (greatest odds for Mexican patients, aOR, 1.44; P < .001). CONCLUSION: Hispanic/Latinx patients with non–small-cell lung cancer were more likely to be diagnosed with advanced disease compared with NHWs. Disparities persisted upon disaggregation by both race and country of origin, with over half of Mexican patients with metastatic disease at diagnosis. Disparities among Hispanic/Latinx groups by race and by country of origin highlight the shortcomings of treating these groups as a monolith and underscore the need for disaggregated research and targeted interventions.